During the 2000s, anti-HER2 therapies were developed as one of the first targeted systemic treatment options, changing dramatically the management and prognosis of HER2-positive breast cancer; in the same decade, genome expression profiling was deployed in routine practice, further improving the personalisation of breast cancer treatments [29]. This evidence concerns the gene ERBB2 and breast cancer.